Amylyx (AMLX) Q4 2025 earnings review
Pure-Play Clinical Execution Backed by Solid Cash Runway
Amylyx has successfully completed its painful transition back to a clinical-stage biotech following the 2024 withdrawal of its only commercial product. With revenue at absolute zero, the investment thesis is now entirely tied to pipeline execution and cash management. Q4 results show a tight grip on expenses: Net Loss was stable at $33.0 million, and a massive $317 million cash pile ensures funding into 2028. The core driver—the pivotal Phase 3 LUCIDITY trial for Avexitide in Post-Bariatric Hypoglycemia (PBH)—has successfully completed recruitment, locking in a Q3 2026 data readout. However, the glaring omission of updates on legacy AMX0035 programs raises questions about the fate of the broader pipeline.
🐂 Bull Case
With $317M in cash and a quarterly burn rate stabilizing around $35M, Amylyx has a runway into 2028. This fully funds the company past the critical Q3 2026 Avexitide data readout and into potential commercialization in 2027.
Recruitment for the Phase 3 LUCIDITY trial is complete. With five prior positive clinical trials validating the mechanism, the probability of a successful outcome in Q3 2026 is higher than a typical Phase 3 biotech asset.
🐻 Bear Case
The company has no commercial products. If the LUCIDITY trial fails to meet its endpoints in Q3 2026, the company's valuation will face a catastrophic collapse.
Management heavily promoted AMX0035 trials for PSP and Wolfram syndrome earlier in 2025. The Q4 release completely omits clinical updates on these programs, noting only decreased spending on AMX0035, suggesting these assets may be quietly shelved.
⚖️ Verdict: ⚪
Neutral. The financial discipline is commendable and the Avexitide program is progressing on schedule. However, an investment here is essentially a single-asset binary bet on the Q3 2026 readout.
Key Themes
Avexitide Recruitment Complete
The pivotal Phase 3 LUCIDITY trial (evaluating avexitide in ~75 participants with PBH following Roux-en-Y gastric bypass) has completed recruitment. This is a crucial milestone following minor timeline delays flagged in Q3. Topline data is locked in for Q3 2026. This secures the trajectory toward a potential 2027 commercial launch in a U.S. market estimated at 160,000 patients with no FDA-approved therapies.
Expanding the GLP-1 Antagonist Platform
Amylyx is accelerating its pipeline beyond a single asset by nominating AMX0318 as a new development candidate for PBH and other rare diseases. Discovered via the Gubra A/S collaboration, this novel GLP-1 receptor antagonist showed strong preclinical pharmacokinetics supporting long-acting administration. IND-enabling studies are underway with a filing targeted for 2027, providing a crucial follow-on asset to Avexitide.
AMX0114 Progresses in ALS
The company maintains a foothold in ALS with AMX0114, an investigational ASO targeting calpain-2 with Fast Track Designation. Cohort 1 of the Phase 1 LUMINA trial showed the drug was generally well-tolerated with no treatment-related serious adverse events. Cohort 2 enrollment is slated to finish in March 2026, with biomarker data expected in H1 2026.
The Silent Disappearance of AMX0035
Throughout early 2025, management touted upcoming readouts for AMX0035 in Progressive Supranuclear Palsy (PSP) and Wolfram syndrome. The Q4 2025 press release contains zero clinical updates on these programs. Instead, management notes R&D expenses decelerated 'primarily due to a decrease in spending on AMX0035.' This specific drop in spending directly contradicts earlier narratives about advancing a pivotal Phase 3 trial for Wolfram syndrome in H2 2026.
Macro Threat: GLP-1 Weight Loss Drugs Impacting Bariatric Surgery
While management estimates a 160,000-patient market for PBH, the broader macro environment poses a long-term threat. The explosive adoption of GLP-1 agonists (like Wegovy/Zepbound) for weight loss has the potential to drastically reduce the volume of future bariatric surgeries, ultimately shrinking the addressable market for Avexitide over the next decade.
Narrow Label Risk for Avexitide
The Phase 3 LUCIDITY trial is restricted strictly to patients who have undergone Roux-en-Y gastric bypass. While this reduces trial heterogeneity, it introduces the risk that the initial FDA label may exclude the large population of patients who underwent sleeve gastrectomies, requiring further trials and capital to unlock the full market.
Other KPIs
Total operating expenses remain stable and highly controlled. R&D expenses were $21.2M and SG&A expenses were $15.4M. The discipline shown throughout 2025 proves management can operate leanly while advancing a Phase 3 trial.
Decelerating significantly compared to the $301.7 million net loss in FY24. The 2024 figure included massive one-time costs related to the RELYVRIO discontinuation (inventory impairment, restructuring). The $144.7M represents the clean, ongoing burn rate for the current clinical pipeline.
Guidance
Accelerating. Previous guidance in early 2025 projected a runway only through the end of 2026. The combination of the $191M public offering in Q3 2025 and strict cost controls has successfully extended the runway deep into 2028, completely removing near-term financing overhangs.
Stable compared to the revised guidance issued in Q3 2025. With recruitment now officially complete, the timeline to this massive binary catalyst is firmly locked.
Key Questions
AMX0035 Status
The Q4 release notes a decrease in spending on AMX0035 for ALS and PSP, but provides no clinical updates. Have the ORION (PSP) and HELIOS (Wolfram) trials been formally paused or discontinued?
Commercial Build-Out Strategy
With the cash runway extended into 2028 and a potential avexitide launch in 2027, when will the company begin ramping up SG&A expenses to build the necessary commercial and medical affairs infrastructure?
AMX0318 Development Plan
Now that AMX0318 has been nominated as a development candidate with an IND target of 2027, what specific rare disease indications outside of PBH are being prioritized for its clinical development?